Neurological Biomarkers Market

Neurological Biomarkers Market Sizes By Type (Genomics Biomarkers, Proteomics Biomarkers, Metabolomics Biomarkers, Imaging Biomarkers and Others), By Application (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis and Others), By End-user (Hospital Laboratories, Independent Clinical Diagnostic Centers and Research Organizations), Regions, Global Industry Analysis, Share, Growth, Trends, and Forecast 2024 to 2033

Base Year: 2023 Historical Data: 2020-22
  • Report ID: TBI-14606
  • Published Date: Nov, 2024
  • Pages: 239
  • Category: Healthcare
  • Format: PDF
Buy @ $4700.00 Request Sample PDF

The global neurological biomarkers market was valued at USD 8.10 Billion in 2023 and is anticipated to grow at a CAGR of 11.8% from 2024 to 2033. Neurological biomarkers play a crucial role in diagnosing various diseases, including autism, Parkinson's disease, and depression. They encompass metabolomics as well as imaging-based, genomic-based, and proteomic-based markers. These biomarkers can be categorized into four major types: metabolomics, imaging technologies, genomics studies, and proteomics analyses. Utilizing these biomarkers enhances the treatment efficacy for neurological disorders by expediting drug development processes while enabling earlier diagnoses through non-invasive methods. Additionally, digital biomarkers provide pharmaceutical companies with significant insights that support better decision-making during clinical trials—further driving growth within the neurological biomarker market.

Market Introduction:

A neurological biomarker refers to any biological substance or characteristic that can be objectively measured and assessed as an indicator of normal or diseased states within the nervous system. These biomarkers are valuable for evaluating the risk of developing neurological conditions, monitoring disease progression, assessing treatment impacts, and predicting patient outcomes. Their utility covers diagnostic, prognostic, and predictive areas, each vital in managing neurological disorders. Neurological biomarkers are measurable indicators that provide insights into neurological processes, disease states, or treatment responses. These biomarkers can aid in diagnosing, monitoring, and predicting outcomes for various neurological conditions. In biological samples like blood and cerebrospinal fluid (CSF) and through imaging data, they offer a glimpse into the brain's functional mechanisms and disorders. Recently, these biomarkers have attracted considerable interest due to their potential impact on neurology by facilitating earlier detection of diseases such as Alzheimer's and Parkinson's disease, improving patient stratification, and enabling more personalized treatment procedures for multiple sclerosis and stroke, among other conditions.

Neurological Biomarkers Market Size

Get an overview of this study by requesting a free sample

Recent Development
  • In April 2024: Labcorp introduced an innovative test for glial fibrillary acidic protein (GFAP), a vital blood-based marker crucial for the early identification of neurodegenerative diseases and neurological injuries. This groundbreaking GFAP test provides physicians with a more streamlined approach to evaluating the presence and progression of conditions like Alzheimer's disease, multiple sclerosis, glioblastoma, and traumatic brain injury (TBI).        

Market Dynamics:

Drivers

Rising Prevalence of Neurological Disorders - A key factor propelling the global neurological biomarkers market is the rising incidence of neurological disorders worldwide. Diseases such as Alzheimer's, Parkinson's, multiple sclerosis, and epilepsy are increasingly prevalent, particularly among elderly populations. As the number of people over 65 years old is anticipated to increase significantly in the coming decades, so too will those affected by neurodegenerative and age-related brain diseases. The World Health Organization (WHO) reports that about a billion individuals currently suffer from neurological conditions globally—with Alzheimer's and other dementias ranking high among causes of disability and mortality in older adults. This growing prevalence fosters demand for neurological biomarkers crucial for early diagnosis and effective management tools for these ailments—thereby driving market growth. This factor is stimulating the market growth and development.

Restraints:

High Manufacturing Costs – The development and validation of neurological biomarkers are both lengthy and expensive trials. This process demands identifying potential biomarkers and confirming their validity through extensive preclinical and clinical testing, a journey that can span several years and necessitates significant financial investment. Expenses rise even further when specialized assays or cutting-edge technologies like genomics, proteomics, or imaging are involved. Moreover, the development phase often requires multiple optimization cycles to guarantee accuracy, sensitivity, and specificity—factors that drive up costs. These substantial financial requirements restrict the number of organizations capable of engaging in biomarker research and development activities, ultimately slowing market expansion. This factor is limiting the market growth.

Opportunities:

Growing Awareness and Early Diagnosis Initiatives - Awareness campaigns and early diagnosis efforts by healthcare organizations and patient advocacy groups have been pivotal in advancing the neurological biomarkers market. As familiarity with neurological diseases expands, there is a growing demand for diagnostic tools that support early intervention. This aspect is especially important for neurodegenerative conditions like Alzheimer's and Parkinson's, where treatments are most effective when administered at an early stage of the disease. Organizations such as the Alzheimer's Association and Parkinson's Foundation actively encourage early screening and diagnosis, boosting demand for biomarkers capable of detecting these diseases before major symptoms develop. Thus, public awareness initiatives combined with a focus on early diagnosis have created a supportive environment for growth in the neurological biomarker sector. This factor is anticipated to provide lucrative growth opportunities in the upcoming years.

Regional segmentation analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America region emerged as the most prominent Neurological biomarkers market, with a 38.0% market revenue share in 2023. The U.S. country hosts numerous prominent biotechnology and pharmaceutical firms that focus extensively on biomarker research, especially in the fields of Alzheimer's disease, Parkinson's disease, and multiple sclerosis. This effort is supported by private sector investments and government organizations/associations like the National Institutes of Health (NIH), ensuring a steady flow of resources toward neurological biomarker development. The NIH allocates billions each year to neurological research projects, including initiatives for discovering biomarkers to enhance diagnosis and treatment options. These substantial investments greatly enhance North America's ability to innovate new biomarkers and bring them to market, strengthening its global competitive position. The regional market players also engage in various market strategies such as product innovation, product differentiation, mergers, acquisitions, partnerships, and strategic alliances to maintain their competitive edge.

North America Region Neurological Biomarkers Market Share in 2023 - 38.0%

 

www.thebrainyinsights.com

Check the geographical analysis of this market by requesting a free sample

  • In July 2023: Quanterix Corporation has introduced LucentAD, a biomarker blood test designed to aid in diagnosing Alzheimer’s disease in patients.
Type Segment Analysis

The type segment includes genomics biomarkers, proteomics biomarkers, metabolomics biomarkers, imaging biomarkers and others. The proteomics biomarkers segment dominated, with a market share of around 38% in 2023. Numerous advanced systems can detect and measure low concentrations of proteomic neurological biomarkers. For instance, Merck's SMCxPRO technology can quantify proteins in blood plasma samples, aiding the management of neurological disorders like Alzheimer's disease. This capability has facilitated early diagnosis of such conditions, driving market expansion. Furthermore, recent enhancements in instrument sensitivity and reproducibility—including LC-MS/MS technologies, microarray advancements, and breakthroughs in immunoassay-based single-molecule quantification and multiplexing—are significantly advancing research into proteomics-based biomarkers.

End-user Segment Analysis

The end-user segment includes hospital laboratories, independent clinical diagnostic centers and research organizations. The research organizations segment dominated, with a market share of around 42% in 2023. Research institutions like the National Institute of Neurological Disorders and Stroke (NINDS) have offered substantial funding for discovering, validating, and qualifying biomarkers related to various neurological disorders. In May 2022, Amprion Inc. was awarded an additional research grant from NINDS, totaling approximately USD 730,000, to further validate its SYNTap Biomarker Test aimed at diagnosing neurological diseases or disorders.

Application Segment Analysis

The application segment includes Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis and others. The Alzheimer’s Disease segment dominated, with a market share of around 37% in 2023. The rising incidence of Alzheimer's disease, coupled with increased clinical trials and research focused on AD drug development, is contributing to the segment's growth. Biomarkers play a crucial role in diagnosing the condition by indicating target engagement, supporting efforts for disease modification, and ensuring safety through testing. The rapid expansion of the elderly population—who are at greater risk for Alzheimer's—further drives market growth. According to the Alzheimer's Association, nearly 55 million people worldwide currently have dementia—a figure projected to rise to 77 million by 2030 and approximately 138 million by 2050. In addition, an estimated 7 million individuals in the U.S. live with Alzheimer's disease.

Some of the Key Market Players:
  • Advanced Brain Monitoring Inc.
  • ACROBIOSYSTEMS INC.
  • bioMerieux SA
  • Alseres Pharmaceuticals Inc
  • Bio Rad Laboratories Inc.
  • Enzo Biochem Inc.
  • Charles River Laboratories
  • Fujirebio Holdings Inc.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Abbott Laboratories
  • IQVIA Holdings Inc.
  • EATRIS ERIC

Report Description: 

Attribute Description
Market Size Revenue (USD Billion)
Market size value in 2023 USD 8.10 Billion
Market size value in 2033 USD 24.71 Billion
CAGR (2024 to 2033) 11.8%
Historical data 2020-2022
Base Year 2023
Forecast 2024-2033
Region The regions analyzed for the market are Asia Pacific, Europe, South America, North America, and Middle East & Africa. Furthermore, the regions are further analyzed at the country level.
Segments Type, Application, End-user   

Frequesntly Asked Questions

As per The Brainy Insights, the size of the global neurological biomarkers market was valued at USD 8.10 billion in 2023 to USD 24.71 billion by 2033.

The global neurological biomarkers market is growing at a CAGR of 11.8% during the forecast period 2024-2033.

North America region became the largest market for neurological biomarkers.

The rising prevalence of neurological disorders in developed and developing countries is driving the market's growth.

Request Table of Content

+1

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. The Brainy Insights has segmented the global neurological biomarkers market based on below-mentioned segments:

Global Neurological Biomarkers Market by Type:

  • Genomics Biomarkers
  • Proteomics Biomarkers
  • Metabolomics Biomarkers
  • Imaging Biomarkers
  • Others

Global Neurological Biomarkers Market by End-user:

  • Hospital Laboratories
  • Independent Clinical Diagnostic Centers
  • Research Organizations

Global Neurological Biomarkers Market by Application:

  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Autism Spectrum Disorder
  • Others

Global Neurological Biomarkers Market by Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
  • South America
    • Brazil
  • Middle East and Africa  
    • UAE
    • South Africa

Methodology

Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision. 

Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.

The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.

Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:

MARKET RESEARCH PROCESS

Data Procurement:

The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.

The data procurement stage involves in data gathering and collecting through various data sources.

This stage involves in extensive research. These data sources includes:

Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:

  • The organizational databases such as D&B Hoovers, and Bloomberg that helps us to identify the competitive scenario of the key market players/organizations along with the financial information.
  • Industry/Market databases such as Statista, and Factiva provides market/industry insights and deduce certain formulations. 
  • We also have contractual agreements with various reputed data providers and third party vendors who provide information which are not limited to:
    • Import & Export Data
    • Business Trade Information
    • Usage rates of a particular product/service on certain demographics mainly focusing on the unmet prerequisites

Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.

Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.

The supply side for a domain specific market is analysed by:

  • Estimating and projecting penetration rates through analysing product attributes, availability of internal and external substitutes, followed by pricing analysis of the product.
  • Experiential assessment of year-on-year sales of the product by conducting interviews.

The demand side for the market is estimated through:

  • Evaluating the penetration level and usage rates of the product.
  • Referring to the historical data to determine the growth rate and evaluate the industry trends

In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.

Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:

  • Applying demographic along with psychographic segmentation for market evaluation
  • Determining the Micro and Macro-economic indicators for each region 
  • Examining the industry indicators prevailing in the market. 

Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:

  • Data Screening: Data screening is the process of scrutinising data/information collected from primary research for errors and amending those collected data before data integration method. The screening involves in examining raw data, identifying errors and dealing with missing data. The purpose of the data screening is to ensure data is correctly entered or not. The Brainy Insights employs objective and systematic data screening grades involving repeated cycles of quality checks, screening and suspect analysis.
  • Data Integration: Integrating multiple data streams is necessary to produce research studies that provide in-depth picture to the clients. These data streams come from multiple research studies and our in house database. After screening of the data, our analysts conduct creative integration of data sets, optimizing connections between integrated surveys and syndicated data sources. There are mainly 2 research approaches that we follow in order to integrate our data; top down approach and bottom up approach.

Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.

This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.

Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.

The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:

  • CXOs and VPs of leading companies’ specific to sector
  • Purchasing managers, technical personnel, end-users
  • Key opinion leaders such as investment bankers, and industry consultants

Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.

Some Facts About The Brainy Insights

50%

Free Customization

300+

Fortune 500 Clients

1

Free Yearly Update On Purchase Of Multi/Corporate License

900+

Companies Served Till Date